NEW YORK – Natera said on Monday that Medicare Administrative Contractor Noridian has issued positive coverage for its Prospera donor-derived cell-free DNA organ transplant test.
In addition, Noridian is developing a generic policy for dd-cfDNA tests that will include several commercially available tests. Prospera's coverage will be under this new policy in the future, Natera said.
Noridian's decision follows final local coverage determinations (LCDs) Natera received for Prospera from Palmetto last December and from Wisconsin Physicians Service Insurance Corporation last February.
The Prospera test uses Natera's SNP-based massively multiplexed PCR technology to measure the fraction of donor-derived cell-free DNA in the recipient's blood. It can be used to help rule in or out active rejection of an organ.
Natera is currently evaluating the test in the ProActive study, which has enrolled more than 145 patients so far, and is offering it through an early-access program.
"We are very pleased with the overwhelmingly positive comments received from the transplant community during the Medicare open comment period, and to have received positive coverage for the Prospera test," said Phil Gauthier, Natera's medical director of transplant, in a statement.